Published on Monday, 11 November 2013
Written by Liz Highleyman
HIVandHepatitis.com
A dual regimen of entecavir (Baraclude) plus tenofovir (Viread) for 48 weeks led to virological response and was generally well-tolerated as second-line therapy for chronic hepatitis B patients who had failed previous nucleoside/nucleotide treatment, according to a poster presentation at the 64th AASLD Liver Meeting last week in Washington, DC. Continue reading "Entecavir + Tenofovir Works Well for Hepatitis B Patients with Prior Treatment Failure"